A Phase I Study of Oral UE2343 in Healthy Subjects

Healthy Clinical Trial

— UE2343  

Official title:

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral UE2343 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01770886
• Other study ID #: UE2343
• Status: Completed
• Phase: Phase 1
• First received: January 10, 2013
• Last updated: July 16, 2013
• Start date: January 2013
• Est. completion date: July 2013

Study information

• Verified date: July 2013
• Source: University of Edinburgh
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

A randomised, double-blind, placebo-controlled, phase I study in healthy subjects. Safety, pharmacokinetic and pharmacodynamic data will be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: July 2013
• Est. primary completion date: July 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy male and female subjects between 18 and 65 years of age (inclusive).

• Female subject is postmenopausal or surgically sterilized or had a hysterectomy.

• Female subject with negative pregnancy test.

• Male subjects willing to use an effective method of contraception, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from Day 1 until 3 months afterwards.

• Subject with a Body Mass Index (BMI) of 18-30 kg/m2. Body Mass Index = Body weight (kg) / [Height (m)]2.

• Subject with no clinically significant abnormal serum biochemistry, haematology and urine examination values or results suggesting an infectious or other systemic disorder. The parameters to be measured will include those shown in Appendix 2. The Simbec normal ranges are shown in Appendix 3.

• Subject with a negative urinary drugs of abuse screen (Appendix 2) (N.B. a positive alcohol result may be repeated at the discretion of the Investigator).

• Subject with negative HIV and Hepatitis B and C results.

• Subject with no clinically significant abnormalities in 12-lead electrocardiogram (ECG).

• no clinically significant abnormalities in vital signs.

• willing and able to comply with the requirements of the protocol.

• satisfy a medical examiner about fitness to participate in the study.

• provide written informed consent to participate in the study.

• Smokers are eligible to participate in the study.

Exclusion Criteria:

• Relevant abnormality in medical history or on examination, including history of dementia, or other psychiatric, neurological, immunological, respiratory or cardiovascular disorder. Particularly exclude subjects with signs of peripheral neuropathy. Abnormal laboratory findings suggesting the presence of a systematic disorder.

• Participation in a clinical study of an unlicensed drug in the previous 4 months, or a marketed drug study within the previous 3 months. (N.B. washout period between trials defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).

• Known allergies, including allergy to chemicals like and excipients associated with UE2343.

• Recent or clinically significant history of drug or alcohol abuse.

• Blood donation greater than 500 ml in the previous 3 months.

• Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).

• Receipt of regular prescribed medication within 7 days of the first study day and / or receipt of vitamins, minerals, herbal remedies and nutritional supplements within 7 days of the first study day. Subjects taking long lasting drugs more than 7 days before the study may be excluded at the physician's discretion. Inclusion of subjects who have taken over the counter drugs during this period will be reviewed on a case-by-case basis in relation to the safety aspects and objectives of this study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• UE2343
Oral capsule
• Placebo
Oral capsule

Locations

Country	Name	City	State
United Kingdom	Simbec Research	Merthyr Tydfil

Sponsors (3)

Lead Sponsor	Collaborator
University of Edinburgh	Simbec Research, Wellcome Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of UE2343 in healthy male/female subjects	Days 1-2 at each dose: 12 lead ECG; Vital signs; Symptom led clinical assessment (day 1 only); Routine laboratory assessments; Days 3-6 at each dose: 12 lead ECG; Vital signs; Routine laboratory assessments; Day 10 at each dose: 12 lead ECG; Vital signs; Routine laboratory assessments; Physical examination; Pregnancy test	At each dose	Yes
Secondary	Pharmacokinetic parameters of UE2343 and pharmacodynamic exposure	Days 1-2 at each dose: Blood and urine samples for measurement of UE2343; Blood samples for adrenal androgens; Blood samples for ACTH and cortisol; Urine samples for urinary free steroids; Days 3-6 at each dose: Blood and urine samples for measurement of UE2343; Blood samples for adrenal androgens; Blood samples for ACTH and cortisol; Urine samples for urinary free steroids	At each dose	No